Gene Therapy Market Opportunity For CMOs – 2019 PharmSource Edition
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
This report will explore whether the bio/pharma industry is adequately prepared for future gene therapy developments and whether CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity. This report is a companion to Cell Therapy Market Opportunity for CMOs – 2018 Edition, GlobalData PharmSource, July 2018.
Scope
This 47-page report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for:
• CMO executives who must have deep understanding of the gene therapy marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Pharmaceutical and Biotech companies involved in the development of gene therapies or gene therapy technologies.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
What are the characteristics of the gene therapy pipeline?
What volumes of viral vector will be required by 2024 for clinical and commercial gene therapy manufacturing, and how many bioreactors will be needed?
How many gene therapies from the current clinical pipeline are predicted to be approved?
What gene therapies have been approved by the FDA and EMA to date?
What is the geographic reach of gene therapy contract manufacturing organizations and what methods of transfection do they use?
What are the steps in the in vivo and ex vivo gene therapy supply chains?
What is the contract manufacturing organization opportunity for gene therapies?
What are the top therapy areas and indications for gene therapy clinical trials, 2013-2019?
How can the gene therapy manufacturing process be made more efficient?
What investments have contract manufacturing organizations and bio/pharmaceutical companies made in gene therapy manufacturing facilities and technologies?
Advanced BioScience Laboratories Inc
Adverum Biotechnologies Inc
Alliance for Regenerative Medicine
Amicus Therapeutics Inc
Applied Genetic Technologies Corp
AskBio
Atvio Biotech Ltd
Audentes Therapeutics Inc
AveXis Inc
Axovant Sciences Ltd
Batavia Biosciences BV
Benitec Biopharma Ltd
Biogen Inc
BioNTech SE
BioReliance Corp
Biovian Oy
bluebird bio
Brammer Bio LLC
Candel Therapeutics
Candel Therapeutics
Catalent Inc
Cell & Gene Therapy Catapult
Centre for Commercialization of Regenerative Medicine
Charles River Laboratories International Inc
City of Hope
Clinical BioManufacturing Facility
Cobra Biologics Ltd
Delphi Genetics SA
EMA
Emergent BioSolutions Inc
Evitria SA
Expression Systems LLC
FDA
FinVector Oy
FKD Therapies Oy
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung eV
Fujifilm Diosynth Biotechnologies USA Inc
GE Healthcare
GenIbet Biopharmaceuticals SA
Genscript Biotech Corp
Genzyme Corp
GlaxoSmithKline Plc
Helixmith Co Ltd
Hitachi Chemical Co Ltd
Huazhong University of Science & Technology
Human Stem Cells Institute
iCarTAB BioMed Inc
ID Pharma Co Ltd
IDT Biologika GmbH
Instituto de Biologia Experimental e Tecnologica
International Society for Cellular Therapy
Kaneka Eurogentec SA
King's College London
LakePharma Inc
Lonza Group Ltd
MassBiologics
MeiraGTx
Memorial Sloan Kettering Cancer Center
Merck & Co Inc
Merck KGaA
Meridian Life Science Inc
Mitsubishi Tanabe Pharma Corp
MolMed SpA
MTG Biotherapeutics Inc
Nationwide Children's Hospital
NCI Biopharmaceutical Development Program
Neurotech Pharmaceuticals Inc
Nightstar Therapeutics PLC
Novartis
Novasep Holding SAS
OncoSec Medical Inc
Orchard Therapeutics Plc
Orgenesis
Oxford BioMedica Plc
Oxford Genetics Ltd
Paragon Bioservices Inc
Pfizer Inc
Polyplus
RegenxBio Inc
Sangamo Therapeutics Inc
Sanofi
Sarepta Therapeutics Inc
Shenzen SiBiono GeneTech Co Ltd
Sorrento Therapeutics Inc
Spark Therapeutics Inc
Symbiosis Pharmaceutical Services Ltd
Takara Bio Inc
Thermo Fisher Scientific
Tocagen Inc
UNC Vector Core
UniQure NV
Vascular Biogenics Ltd
Vibalogics GmbH
ViGene Biosciences Inc
ViralGen
Virovek InCorp
Voyager Therapeutics
Waisman Biomanufacturing
WuXi AppTec (Shanghai) Co Ltd
WuXi Biologics Co Ltd
Yposkesi SAS
Zelluna Immunotherapy
ZIOPHARM Oncology Inc
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.